🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU American Thoracic Society (ATS)

A new COPD diagnostic schema that includes chest imaging, respiratory symptoms, and spirometry identified more high-risk individuals and excluded low-risk ones. #ATS2025 ja.ma/4dp9i30

1/2 New pub in JAMA from #CLAIR! New Diagnostic Schema for #COPD 15.4%⬆️COPD among smokers; 6.4%⬇️ diagnosis among airflow obstruction but no symptoms/imaging findings. Newly detected have high risk of mortality, exacerbations and FEV1 decline jamanetwork.com/journals/jama/…

📌 A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease, presented today at #ATS2025 in the Discussions on the Edge session. ➡️ Free to read online from JAMA! ja.ma/4iQwsjJ

📌 A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease, presented today at #ATS2025 in the Discussions on the Edge session. ➡️ Free to read online from JAMA. ja.ma/4j9eCZk

JAMA paper in this morning’s session highlighting the complexity of diagnosing COPD. jamanetwork.com/journals/jama/…. This also illustrates why we need investment in development of better tests to diagnose respiratory diseases; it’s incredibly costly + time-consuming

Join us this afternoon for a #ScientificSymposium! "DIAGNOSIS OF COPD: A PRO CON DEBATE" 📆 5/19/25, 2:15-3:45PM 📍 Room 2009/2011 (West Building, Level 2), Moscone Center Chairs: Jessica Bon , Surya P Bhatt, MD, MSPH , Nicola A. Hanania #ATS2025

Join us at ATS American Thoracic Society (ATS) C2 TYPE 2 INFLAMMATION IN COPD: A PRO AND CON DEBATE Room 3014/3016/3018 (West Building, Level 3), Moscone Center Tuesday, May 20 9:15 AM - 10:45 AM Francesca Polverino Surya P Bhatt, MD, MSPH Don Sin

New Diagnostic Approach for COPD jamanetwork.com/journals/jama/…

A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease: this new #COPD diagnostic schema, which includes chest imaging, respiratory symptoms, and spirometry, identified additional individuals at risk for poor respiratory outcomes. ivancevichmd.blogspot.com/2025/05/copdge…

Newly proposed diagnostic schema for COPD using major and minor criteria classifies individuals as having this disease beyond airflow limitation and identifies individuals at increased risk for poor outcomes. doi:10.1001/jama.2025.7358 JAMA

📣Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as having #COPD, according to research presented at #ATS2025 and published in JAMA. Surya P Bhatt, MD, MSPH American Thoracic Society (ATS) healio.com/news/pulmonolo…

🗨️"The new diagnostic schema integrates #spirometry, #imaging and respiratory #symptoms and aims to provide a more precise diagnosis of #COPD," Surya P Bhatt, MD, MSPH, MD, UAB, told Healio. healio.com/news/pulmonolo…

“Redefining COPD” GOLD 2025 🔑 Top 10 Clinical Pearls – Redefining COPD (JAMA 2025, GOLD 2025) 📉 COPD = Not Just Spirometry Anymore! GOLD 2025 still mandates post-bronchodilator FEV₁/FVC < 0.70 — but this alone may miss or misclassify COPD in many. 🧠 NEW Diagnostic

Surya P Bhatt, MD, MSPH reported in JAMA Network that a new COPD diagnostic approach better identified patients with COPD and excluded those with airflow obstruction but no symptoms or lung damage. UAB Pulmonary 📰 Learn more! ▶️ jamanetwork.com/journals/jama/…

Lung Function Decline in Smokers with Normal Spirometry: The Devastating Impact of Lung Attacks American Thoracic Society (ATS) 🔓Open Access 🔗atsjournals.org/doi/abs/10.116…

Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry American Thoracic Society (ATS) Internal Medicine at Iowa #COPD 🔗atsjournals.org/doi/full/10.11…

Among patients with #COPD and type 2 #inflammation, investigator-reported #emphysema did not change benefits seen with #dupilumab, according to data at #ATS2025. American Thoracic Society (ATS) Surya P Bhatt, MD, MSPH healio.com/news/pulmonolo…

💬"The findings of this study indicate that the benefits of #dupilumab in patients with #COPD and type 2 inflammation ... are also applicable to those with #emphysema," Surya P Bhatt, MD, MSPH, UAB Pulmonary, told Healio. #ATS2025 healio.com/news/pulmonolo…